FDA-Compliant Vaccine Manufacturing and Supply

The contract involves the manufacture of a Japanese Encephalitis Vaccine (JEV) in single-dose prefilled syringes, requiring strict compliance with FDA regulations and adherence to the Medical Product Identification Number 5 guidelines effective July 23, 2024. The work must be performed at a facility in Philadelphia with a zip code of 19111, and the production process must meet all federal standards for safety, efficacy, and quality control applicable to biological products intended for human use. The contract is classified as a subcontract under the NAICS code 325414, which pertains to vaccine and other biological substance manufacturing, and is issued by the Department of Defense through DLA Troop Support. The solicitation was posted on May 12, 2026, with a response deadline of May 29, 2026, at 3:59 AM Eastern Time. No set-aside designation is specified, meaning the opportunity is open to all eligible contractors regardless of business size or status. The contract does not include a designated point of contact, and prospective bidders are expected to navigate the process through the provided SAM.gov workspace link. The end product is critical for public health preparedness and must be delivered in a ready-to-administer format, ensuring rapid deployment capabilities for military and civilian populations in high-risk areas.